Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency
- Category: Proteins and Peptides
- Published on Monday, 03 June 2019 20:48
- Hits: 665
Topline Data from PEACE Anticipated in First Quarter of 2021
New Data from ARG1-D Phase 1/2 Extension Study Expected in September 2019
AUSTIN, TX, USA I June 03, 2019 I Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today announced the dosing of the first patient in the Company’s Phase 3 PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints) clinical trial. The pivotal trial is intended to further evaluate the efficacy and safety of pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D), a progressive disease presenting in early childhood that results in severe complications and early mortality. The Company expects to report topline data from the PEACE trial in the first quarter of 2021. Aeglea anticipates reporting new data in September 2019 from all patients who have each received at least 20 doses in the Company’s ongoing Phase 1/2 extension study.
"Aeglea is reminded daily of the challenges patients with ARG1-D face due to the limitations of current disease management," said Anthony G. Quinn, M.B. Ch.B, Ph.D., president and chief executive officer of Aeglea. “The dosing of our first patient in the pivotal Phase 3 PEACE trial is a major step in establishing the clinical effectiveness of pegzilarginase. Aeglea is committed to working with physicians, patients, caregivers, and the ARG1-D community as we advance this potentially transformative therapy for patients with this devastating and progressive disease.”
“We are excited to be involved in the PEACE trial as it provides us the opportunity to build on our experience and data from the Phase 1/2 trial, where we observed excellent control of arginine levels and stability or improvement in mobility and adaptive behavior,” said Markey McNutt, M.D., Ph.D. an assistant professor with the Eugene McDermott Center for Human Growth and Development at UT Southwestern.
PEACE is a global, randomized, double-blind trial designed to assess the effects of treatment with pegzilarginase versus placebo over 24 weeks with a primary endpoint of statistically significant plasma arginine reduction from baseline. The primary endpoint assesses the effectiveness of pegzilarginase in lowering plasma arginine levels given the evidence that plasma arginine control has the potential to improve the clinical status and to slow disease progression in patients with ARG1-D. Secondary endpoints will include mobility and adaptive behavior as assessments of clinically meaningful effects, in addition to safety and pharmacokinetics. Upon completion of the 24-week treatment period, patients may qualify to participate in a long-term extension study of pegzilarginase.
About Pegzilarginase in Arginase 1 Deficiency
Pegzilarginase is an enhanced human arginase that enzymatically depletes the amino acid arginine. Aeglea is developing pegzilarginase for the treatment of patients with Arginase 1 Deficiency, a rare debilitating disease presenting in childhood with persistent hyperargininemia, severe progressive neurological abnormalities and early mortality. Pegzilarginase is intended for use as an enzyme replacement therapy in patients to reduce elevated blood arginine levels. Aeglea’s Phase 1/2 data for pegzilarginase in patients with Arginase 1 Deficiency demonstrated clinical improvements and sustained lowering of plasma arginine. Aeglea is currently recruiting patients for its single, global pivotal Phase 3 PEACE trial designed to assess the effects of treatment with pegzilarginase versus placebo over 24 weeks with a primary endpoint of plasma arginine reduction.
About Aeglea BioTherapeutics
Aeglea is a clinical-stage biotechnology company that engineers next-generation human enzymes with enhanced properties and novel activity to provide solutions for diseases with unmet medical need. Aeglea is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency and in combination with an immune checkpoint inhibitor for small cell lung cancer. Aeglea has two pipeline programs in IND-enabling studies for Homocystinuria and Cystinuria and an active discovery pipeline. For more information, please visit http://aegleabio.com.
SOURCE: Aeglea BioTherapeutics